Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract 6688: Peripheral CCR6⁺ T-cell profile in healthy volunteers after ingestion of Lactobacillus-derived exopolysaccharide which was reported as an ICI-efficacy enhancer in vivo

Hirotaka Kawanabe-Matsuda, Takehiro Yokoo, Shogi Tou, Shoko Ishii, Marie Nakamura, Reiko Watanabe, Miho Ogawa, Kazuyoshi Takeda, Toshihiro Sashihara, Hiroyuki Shimizu

Cancer Res (2024) 84 (6_Supplement): 6688.

https://doi.org/10.1158/1538-7445.AM2024-6688

Published: 22 March 2024

View article titled, Abstract 6688: Peripheral CCR6+ T-cell profile in healthy volunteers after ingestion of Lactobacillus-derived exopolysaccharide which was reported as an ICI-efficacy enhancer in vivo

Journal Articles

Abstract 1721: Diversity evenness of TCR repertoire in the tumor and periphery reflects antitumor activity and immune-related adverse events, respectively

Akihiro Hosoi, Hirokazu Matsushita, Kazuyoshi Takeda, Ryuji Suzuki, Kazuhiro Kakimi

Cancer Res (2018) 78 (13_Supplement): 1721.

https://doi.org/10.1158/1538-7445.AM2018-1721

Published: 01 July 2018

View article titled, Abstract 1721: Diversity evenness of TCR repertoire in the tumor and periphery reflects antitumor activity and immune-related adverse events, respectively

Journal Articles

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

Jing Liu, Stephen J. Blake, Heidi Harjunpää, Kirsten A. Fairfax, Michelle C.R. Yong, Stacey Allen, Holbrook E. Kohrt, Kazuyoshi Takeda, Mark J. Smyth, Michele W.L. Teng

Cancer Res (2016) 76 (18): 5288–5301.

https://doi.org/10.1158/0008-5472.CAN-16-0194

Published: 15 September 2016

View article titled, Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

Includes: Supplementary data

Journal Articles

Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity

Niklas K. Finnberg, Prashanth Gokare, Arunasalam Navaraj, Krystle A. Lang Kuhs, George Cerniglia, Hideo Yagita, Kazuyoshi Takeda, Noboru Motoyama, Wafik S. El-Deiry

Cancer Res (2016) 76 (3): 700–712.

https://doi.org/10.1158/0008-5472.CAN-15-2759

Published: 31 January 2016

View article titled, Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity

Includes: Supplementary data

Journal Articles

Abstract 2926: DR5-targeting sensitizes Lgr5+ stem cells to p53 and Chk2-dependent chemotherapy-induced cell death and produces dose-limiting gastrointestinal toxicity (GIT)

Niklas K. Finnberg, Prashanth Gokare, Arunasalam Navaraj, Krystle A. Lang Kuhs, George Cerniglia, Hideo Yagita, Kazuyoshi Takeda, Noboru Motoyama, Wafik S. El-Deiry

Cancer Res (2015) 75 (15_Supplement): 2926.

https://doi.org/10.1158/1538-7445.AM2015-2926

Published: 01 August 2015

View article titled, Abstract 2926: DR5-targeting sensitizes Lgr5+ stem cells to p53 and Chk2-dependent chemotherapy-induced cell death and produces dose-limiting gastrointestinal toxicity (GIT)

Journal Articles

Abstract 424: Chemokine CXCL14 is a multistep tumor suppressor

Ryu-Ichiro Hata, Kazuhito Izukuri, Yasumasa Kato, Soichiro Sasaki, Chihiro Miyamoto, Tetsu Akasaka, Xiaoyan Yang, Yojiro Maehata, Yoji Nagashima, Kazuyoshi Takeda, Tohru Kiyono, Naofumi Mukaida, Masaru Taniguchi

Cancer Res (2015) 75 (15_Supplement): 424.

https://doi.org/10.1158/1538-7445.AM2015-424

Published: 01 August 2015

View article titled, Abstract 424: Chemokine CXCL14 is a multistep tumor suppressor

Journal Articles

Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAF^V600E-Mutant Metastatic Melanoma

Lucas Ferrari de Andrade, Shin F. Ngiow, Kimberley Stannard, Sylvie Rusakiewicz, Murugan Kalimutho, Kum Kum Khanna, Siok-Keen Tey, Kazuyoshi Takeda, Laurence Zitvogel, Ludovic Martinet, Mark J. Smyth

Cancer Res (2014) 74 (24): 7298–7308.

https://doi.org/10.1158/0008-5472.CAN-14-1339

Published: 14 December 2014

View article titled, Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma

Includes: Supplementary data

Journal Articles

Abstract 3520: Targeting spatiotemporal expression of CD137 on tumor-specific cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy

Kazuhiro Kakimi, Akihiro Hosoi, Shuichi Noji, Hirokazu Matsushita, Kazuyoshi Takeda

Cancer Res (2012) 72 (8_Supplement): 3520.

https://doi.org/10.1158/1538-7445.AM2012-3520

Published: 15 April 2012

View article titled, Abstract 3520: Targeting spatiotemporal expression of CD137 on tumor-specific cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy

Journal Articles

Abstract 1541: NK cells are indispensable for suppression of tumor growth and metastasis in transgenic mice overexpressing chemokine CXCL14/BRAK

Ryu-ichiro Hata, Kazuhito Izukuri, Yasumasa Kato, Kazuyoshi Takeda, Tohru Kiyono, Naofumi Mukaida, Masaru Taniguchi

Cancer Res (2012) 72 (8_Supplement): 1541.

https://doi.org/10.1158/1538-7445.AM2012-1541

Published: 15 April 2012

View article titled, Abstract 1541: NK cells are indispensable for suppression of tumor growth and metastasis in transgenic mice overexpressing chemokine CXCL14/BRAK

Journal Articles

Abstract #1152: Unique effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastases

Daisuke Sugiura, Satoshi Aida, Kaori Denda-Nagai, Mika Kamata-Sakurai, Kazuyoshi Takeda, Hideo Yagita, Tatsuro Irimura

Cancer Res (2009) 69 (9_Supplement): 1152.

Published: 01 May 2009

View article titled, Abstract #1152: Unique effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastases

Journal Articles

Interleukin 21 Enhances Antibody-Mediated Tumor Rejection

Mark J. Smyth, Michele W.L. Teng, Janelle Sharkey, Jennifer A. Westwood, Nicole M. Haynes, Hideo Yagita, Kazuyoshi Takeda, Pallavur V. Sivakumar, Michael H. Kershaw

Cancer Res (2008) 68 (8): 3019–3025.

https://doi.org/10.1158/0008-5472.CAN-07-6019

Published: 15 April 2008

View article titled, Interleukin 21 Enhances Antibody-Mediated Tumor Rejection

Includes: Supplementary data

Journal Articles

Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice

Michele W.L. Teng, Jennifer A. Westwood, Phillip K. Darcy, Janelle Sharkey, Moriya Tsuji, Richard W. Franck, Steven A. Porcelli, Gurdyal S. Besra, Kazuyoshi Takeda, Hideo Yagita, Michael H. Kershaw, Mark J. Smyth

Cancer Res (2007) 67 (15): 7495–7504.

https://doi.org/10.1158/0008-5472.CAN-07-0941

Published: 01 August 2007

View article titled, Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice

Includes: Supplementary data

Journal Articles

Tumor therapy combining the proteasome inhibitor bortezomib with TRAIL death receptor agonists

Thomas Sayers, Alan Brooks, Mark Smyth, Kazuyoshi Takeda, Hideo Yagita, William Murphy, Anil Shanker

Cancer Res (2007) 67 (9_Supplement): 2407.

Published: 01 May 2007

View article titled, Tumor therapy combining the proteasome inhibitor bortezomib with TRAIL death receptor agonists

Journal Articles

Suppression of Stress Protein GRP78 Induction in Tumor B/C10ME Eliminates Resistance to Cell Mediated Cytotoxicity

Shunji Sugawara, Kazuyoshi Takeda, Amy Lee, Gunther Dennert

Cancer Res (1993) 53 (24): 6001–6005.

Published: 01 December 1993

View article titled, Suppression of Stress Protein GRP78 Induction in Tumor B/C10ME Eliminates Resistance to Cell Mediated Cytotoxicity

NARROW

Abstract 6688: Peripheral CCR6⁺ T-cell profile in healthy volunteers after ingestion of Lactobacillus-derived exopolysaccharide which was reported as an ICI-efficacy enhancer in vivo

Abstract 1721: Diversity evenness of TCR repertoire in the tumor and periphery reflects antitumor activity and immune-related adverse events, respectively

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity

Abstract 2926: DR5-targeting sensitizes Lgr5+ stem cells to p53 and Chk2-dependent chemotherapy-induced cell death and produces dose-limiting gastrointestinal toxicity (GIT)

Abstract 424: Chemokine CXCL14 is a multistep tumor suppressor

Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAF^V600E-Mutant Metastatic Melanoma

Abstract 3520: Targeting spatiotemporal expression of CD137 on tumor-specific cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy

Abstract 1541: NK cells are indispensable for suppression of tumor growth and metastasis in transgenic mice overexpressing chemokine CXCL14/BRAK

Abstract #1152: Unique effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastases

Interleukin 21 Enhances Antibody-Mediated Tumor Rejection

Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice

Tumor therapy combining the proteasome inhibitor bortezomib with TRAIL death receptor agonists

Suppression of Stress Protein GRP78 Induction in Tumor B/C10ME Eliminates Resistance to Cell Mediated Cytotoxicity

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only